Sophiris Bio Inc. (NASDAQ:SPHS) shares rose 7.6% during trading on Thursday . The company traded as high as $4.19 and last traded at $4.10, with a volume of 2,576,685 shares trading hands. The stock had previously closed at $3.81.

SPHS has been the subject of a number of analyst reports. Maxim Group reissued a “buy” rating and issued a $4.00 price objective on shares of Sophiris Bio in a research report on Friday, June 10th. Echelon Wealth Partners restated a “buy” rating and set a $5.00 target price on shares of Sophiris Bio in a research note on Friday, June 10th.

The stock has a 50 day moving average price of $2.25 and a 200-day moving average price of $1.71. The company’s market capitalization is $91.17 million.

Sophiris Bio (NASDAQ:SPHS) last issued its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. On average, equities analysts forecast that Sophiris Bio Inc. will post ($0.73) earnings per share for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.